4h

Novo Nordisk investors got unwelcome, when the Danish pharmaceutical giant revealed that its experimental heart medication had come up short in a major clinical trial, sending shares tumbling. The company, known largely for its weight loss and diabetes treatments Wegovy and Ozempic, has spent much of 2026 attempting to demonstrate that its business can expand […] The post Novo Nordisk stock drops as heart drug disappoints appeared first on Rolling Out .